Aged Cost-Benefit Analysis Humans Male Medicare Middle Aged *Prostatic Hyperplasia/complications Quality of Life *Transurethral Resection of Prostate Treatment Outcome United States

Humans Lower Urinary Tract Symptoms/etiology/therapy Male Minimally Invasive Surgical Procedures Perioperative Care Prostatectomy Prostatic Hyperplasia/surgery Prostatic Neoplasms/complications Transurethral Resection of Prostate

Aged Aged 80 and over Humans Male Middle Aged Outcome Assessment Health Care Plant Extracts/administration & dosage Prostatic Hyperplasia/*drug therapy Serenoa Tamsulosin/administration & dosage Urological Agents/administration & dosage *Serenoa repens *benign prostatic hyperplasia *meta-analysis *randomized controlled trials *tamsulosin conflicts of interest with respect to the research authorship and/or publication of this article.

Bladder Cancer Care Consensus

Humans Male Outcome Assessment Health Care Prostatic Hyperplasia *Transurethral Resection of Prostate/statistics & numerical data Treatment Outcome

Blood Transfusion/*mortality Combined Modality Therapy Cystectomy/*mortality Humans *Perioperative Care Prognosis Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder cancer Blood transfusion Cystectomy Meta-analysis Oncology Systematic review

Cystectomy France Humans Lymphatic Irradiation Palliative Care Patient Positioning Radiation Oncology Radiotherapy Dosage Radiotherapy Adjuvant Radiotherapy Conformal Urinary Bladder Neoplasms/diagnostic imaging/pathology/*radiotherapy/surgery Bladder cancer Cancers de la vessie Chemoradiation Chimioradiothérapie French society for radiation oncology Guidelines Radiation therapy Radiothérapie Recommandations Société française de radiothérapie oncologique

Humans Palliative Care Prospective Studies Quality of Life Retrospective Studies *Urinary Bladder Neoplasms/radiotherapy Radiotherapy bladder cancer bleeding palliation

Humans Lymphocytes/*pathology Neutrophils/*pathology *Preoperative Care Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*immunology/*surgery

Cystectomy/*methods Humans Perioperative Care/*methods Postoperative Complications/epidemiology/prevention & control *Recovery of Function Standard of Care Urinary Bladder Neoplasms/*surgery Urologic Surgical Procedures/*methods

Cystectomy/*methods Humans Length of Stay Nutritional Status *Perioperative Care Postoperative Complications/*epidemiology Urinary Bladder Neoplasms/*surgery Wound Healing

Abdominal Muscles/*physiopathology Female *Health Services Needs and Demand Humans Middle Aged Neoplasm Metastasis/*physiopathology Quality of Life/*psychology *Social Support Urinary Bladder Neoplasms/*psychology/*secondary/therapy Bladder cancer Concerns Continent diversion Quality of life Systematic review Unmet supportive care needs

Cystectomy/*methods Humans Length of Stay Postoperative Care/*methods Postoperative Complications/*epidemiology Prospective Studies Recovery of Function Retrospective Studies Standard of Care Urinary Bladder Neoplasms/rehabilitation/*surgery bladder cancer enhanced recovery after surgery meta-analysis postoperative rehabilitation radical cystectomy

*Cystectomy *Health Status Humans Patient Education as Topic/*methods Preoperative Care/*methods Relaxation Therapy/*methods Urinary Bladder Neoplasms/*surgery Bladder cancer Cystectomy Supportive intervention Systematic review PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Critical Pathways Cystectomy/*methods/rehabilitation Humans Length of Stay Postoperative Care/*methods Postoperative Complications/*epidemiology *Standard of Care Urinary Bladder Neoplasms/*surgery Urinary Diversion/*methods/rehabilitation Clinical pathways Collaborative care Cystectomy Enhanced recovery Fast track including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.